Hindustan Bio Sciences Limited
Bombay Stock ExchangeTotal Valuation
Hindustan Bio Sciences Limited carries a market capitalization of 72.58M, placing it among publicly traded companies globally. Its enterprise value stands at 101.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 72.58M |
| Enterprise Value | 101.54M |
Share Statistics
Hindustan Bio Sciences Limited currently has 10.25M shares outstanding.
| Shares Outstanding | 10.25M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hindustan Bio Sciences Limited trades at a trailing price-to-earnings ratio of 478.17. The price-to-sales ratio is 11.27, and the price-to-book ratio stands at 3.87.
| PE Ratio | 478.17 |
| PS Ratio | 11.27 |
| PB Ratio | 3.87 |
| P/TBV Ratio | 9.61 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Hindustan Bio Sciences Limited trades at an EV/EBITDA multiple of 7,327.66 and an EV/FCF ratio of 9,231.33. The EV/Sales ratio of 14.42 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7,327.66 provides insight into valuation relative to core operating earnings.
| EV / Sales | 14.42 |
| EV / EBITDA | 7,327.66 |
| EV / EBIT | 7,327.66 |
| EV / FCF | 9,231.33 |
Financial Position
Hindustan Bio Sciences Limited maintains a current ratio of 38.80, meaning it holds 38.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 284.44, indicating elevated leverage, while an interest coverage ratio of -107.18 demonstrates limited ability to service its debt obligations.
| Current Ratio | 38.80 |
| Quick Ratio | 6.55 |
| Debt / Equity | 284.44 |
| Debt / EBITDA | -19.93 |
| Interest Coverage | -107.18 |
Financial Efficiency
| Return on Equity (ROE) | -3.86 |
| Return on Assets (ROA) | -2.39 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Hindustan Bio Sciences Limited's stock has declined approximately -23.45946% over the past 52 weeks. The 50-day moving average sits at 8.22, while the 200-day moving average is 7.53.
| Beta (5Y) | N/A |
| 52-Week Price Change | -23.45946% |
| 50-Day Moving Average | 8.22 |
| 200-Day Moving Average | 7.53 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hindustan Bio Sciences Limited generated 7.04M in revenue and converted that into -791,000.00 in net income, yielding earnings per share of -0.08. EBITDA reached -1.18M, while operating income came in at -1.18M.
| Revenue | 7.04M |
| Gross Profit | 2.55M |
| Operating Income | -1.18M |
| Pretax Income | -791,000.00 |
| Net Income | -791,000.00 |
| EBITDA | -1.18M |
| EBIT | -1.18M |
| Earnings Per Share (EPS) | -0.08 |
Balance Sheet
Hindustan Bio Sciences Limited holds 1.30M in cash and equivalents against 23.50M in total debt, resulting in a net debt position of 22.19M. Total book value stands at 20.50M, with working capital of 7.52M providing operational flexibility.
| Cash & Cash Equivalents | 1.30M |
| Total Debt | 23.50M |
| Net Debt | 22.19M |
| Equity (Book Value) | 20.50M |
| Book Value Per Share | 2.01 |
| Working Capital | 7.52M |
Margins
Hindustan Bio Sciences Limited operates with a gross margin of 36.26, reflecting its pricing power and cost economics. The operating margin of -16.74 and net profit margin of -11.23 provide insight into operational efficiency.
| Gross Margin | 36.26 |
| Operating Margin | -16.74 |
| Pretax Margin | -11.23 |
| Profit Margin | -11.23 |
| EBITDA Margin | -16.74 |
Scores
Hindustan Bio Sciences Limited posts an Altman Z-Score of 2.39, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.39 |